Ignite Creation Date:
2024-05-06 @ 3:54 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04794699
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2021-03-09
Brief Title:
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Sponsor:
IDEAYA Biosciences
Organization:
IDEAYA Biosciences
Study Overview
Official Title:
An Open Label Phase 1 Treatment Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of IDE397 MAT2A Inhibitor In Adult Participants With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 open-label multicenter dose escalation and expansion study of the safety PK PD and preliminary anti-tumor activity of IDE397 as a single agent and in combination with other anticancer agents including taxanes docetaxel paclitaxel or sacituzumab govitecan SG in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha MAT2A
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None